TORONTO, November 09, 2021–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company“), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15, 2021.

A conference call will be held on the same day at 4:30 p.m. (EST) to discuss the results and recent business updates. The call will be hosted by Doug Drysdale, Cybin’s Chief Executive Officer. Mr. Drysdale and other members of the management team will be available to answer questions from participants following the prepared remarks.


  Subscribe to news from

Be the first to know when breaking news are released.

An archived webcast will also be available on the Company’s Investor Relations site under the Events & Presentations page.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on


Investor & Media Contacts:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
[email protected]

Tim Regan/Scott Eckstein
KCSA Strategic Communications
[email protected]

Lisa M. Wilson
In-Site Communications, Inc.
[email protected]